CN108771687A - 微生物区系的组合物及与其相关的方法 - Google Patents

微生物区系的组合物及与其相关的方法 Download PDF

Info

Publication number
CN108771687A
CN108771687A CN201810321009.0A CN201810321009A CN108771687A CN 108771687 A CN108771687 A CN 108771687A CN 201810321009 A CN201810321009 A CN 201810321009A CN 108771687 A CN108771687 A CN 108771687A
Authority
CN
China
Prior art keywords
subject
microflora
composition
akkermansia
relative abundance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810321009.0A
Other languages
English (en)
Chinese (zh)
Inventor
L·M·卡普兰
A·P·利奥
P·J·特恩博
J·L·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Harvard University
Kenvue Brands LLC
Original Assignee
General Hospital Corp
Ethicon Endo Surgery Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49003107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108771687(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Ethicon Endo Surgery Inc, Harvard University filed Critical General Hospital Corp
Publication of CN108771687A publication Critical patent/CN108771687A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
CN201810321009.0A 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法 Pending CN108771687A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604824P 2012-02-29 2012-02-29
US61/604,824 2012-02-29
CN201380022545.6A CN104780932A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380022545.6A Division CN104780932A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法

Publications (1)

Publication Number Publication Date
CN108771687A true CN108771687A (zh) 2018-11-09

Family

ID=49003107

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810321009.0A Pending CN108771687A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法
CN201910088168.5A Pending CN110201003A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法
CN201380022545.6A Pending CN104780932A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910088168.5A Pending CN110201003A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法
CN201380022545.6A Pending CN104780932A (zh) 2012-02-29 2013-02-28 微生物区系的组合物及与其相关的方法

Country Status (6)

Country Link
US (11) US9173910B2 (https=)
EP (1) EP2836224A4 (https=)
CN (3) CN108771687A (https=)
BR (1) BR112014021388A2 (https=)
IN (1) IN2014DN07752A (https=)
WO (1) WO2013130773A2 (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP4509181A3 (en) 2012-11-19 2025-05-21 Université Catholique de Louvain Utilisation d'akkermansia pour le traitement de troubles métaboliques
HK1222243A1 (zh) * 2012-12-13 2017-06-23 麦太宝根有限公司 鉴定有发生2 型糖尿病风险的人
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
US9549703B2 (en) 2013-11-27 2017-01-24 Elwha Llc Devices and methods for sampling and profiling microbiota of skin
US9811641B2 (en) 2013-08-23 2017-11-07 Elwha Llc Modifying a cosmetic product based on a microbe profile
US20150057623A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Systems, Methods, and Devices for Delivering Treatment to a Skin Surface
US9805171B2 (en) 2013-08-23 2017-10-31 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9526480B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
US10152529B2 (en) 2013-08-23 2018-12-11 Elwha Llc Systems and methods for generating a treatment map
US9557331B2 (en) 2013-08-23 2017-01-31 Elwha Llc Systems, methods, and devices for assessing microbiota of skin
US10010704B2 (en) 2013-08-23 2018-07-03 Elwha Llc Systems, methods, and devices for delivering treatment to a skin surface
US9526450B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
US9610037B2 (en) 2013-11-27 2017-04-04 Elwha Llc Systems and devices for profiling microbiota of skin
EP3134509B1 (en) 2014-04-23 2026-01-21 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
WO2015166489A2 (en) 2014-04-28 2015-11-05 Yeda Research And Development Co. Ltd. Method and apparatus for predicting response to food
WO2015178653A1 (ko) * 2014-05-20 2015-11-26 이화여자대학교 산학협력단 Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
KR101740893B1 (ko) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
WO2016033439A2 (en) * 2014-08-28 2016-03-03 Yale University Compositions and methods for the treating an inflammatory disease or disorder
KR20170066543A (ko) * 2014-10-02 2017-06-14 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 포만 유도 및 포만감 지속이 필요한 대상체에서 포만 유도 및 포만감 지속을 위한 약학 및 식품 조성물
CA2964480A1 (en) * 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016123053A1 (en) * 2015-01-26 2016-08-04 International Dehydrated Foods, Inc. Broth compositions and their use as prebiotics
DK3292135T3 (da) 2015-05-06 2022-10-31 Univ Wageningen Anvendelse af et polypeptid til at fremkalde immunsignalering og/eller påvirke tarmbarrierefunktion og/eller modulere metabolsk status
CA2987863A1 (en) 2015-06-01 2016-12-08 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
WO2016201053A1 (en) * 2015-06-09 2016-12-15 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102569754B1 (ko) 2015-09-10 2023-08-23 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 살균된 아커만시아의 용도
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
CN115887508A (zh) 2016-03-04 2023-04-04 加利福尼亚大学董事会 微生物聚生体及其用途
EP3442546A4 (en) 2016-04-15 2020-03-25 National Health Research Institutes Colon flora compositions against obesity, as well as manufacturing process and use thereof
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
CN109310626A (zh) 2016-04-19 2019-02-05 美利坚合众国,由健康及人类服务部部长代表 革兰氏阴性种治疗特应性皮炎的用途
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
CA3226196A1 (en) 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
US10441612B2 (en) * 2016-08-16 2019-10-15 Taichung Veterans General Hospital Intestinal microbe therapy, composition therefor and method for preparing the same
CN110520111B (zh) * 2016-11-30 2023-12-19 塞诺生物科学股份有限公司 用以管理体重和调节肠道微生物群的药物制剂和方法
CN107043714B (zh) * 2016-12-13 2021-03-12 广州康泽医疗科技有限公司 一种益生菌及其制备方法
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
MX2020004204A (es) * 2017-10-13 2020-08-13 Rebiotix Inc Indice de salud del microbioma.
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
WO2019136236A1 (en) * 2018-01-04 2019-07-11 White Dog Labs, Inc. Method and composition for improving health of an animal comprising cells of organism consisting of the strains within the order clostridiales
EP3773645A4 (en) 2018-04-10 2021-11-24 Siolta Therapeutics, Inc. MICROBIAL CONSORTIA
KR20210013080A (ko) 2018-05-11 2021-02-03 포르테 서브시디어리, 인크. 피부 병태의 치료를 위한 조성물
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
AU2019321681A1 (en) 2018-08-17 2021-02-25 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
AU2019343198A1 (en) * 2018-09-18 2021-05-20 Mcpharma Biotech Inc. Detection, treatment, and monitoring of microbiome-induced metabolic dysfunction
CN110964650B (zh) * 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 一种用于预防和治疗代谢疾病的菌株及其应用
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
EP4010315A4 (en) * 2019-08-09 2023-11-15 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES
WO2021060945A1 (ko) * 2019-09-25 2021-04-01 ㈜헬스바이옴 암 치료를 위한 절대혐기성 인체 장내미생물 및 이의 용도
CN120732903A (zh) 2019-10-07 2025-10-03 谢尔塔治疗公司 治疗性药物组合物
DK180598B1 (da) * 2020-02-21 2021-10-14 Sander Wilbek Theis Stivelsespropanoat anvendt som tilsætningsstof og/eller kosttilskud til mennesker til forebyggelse af overvægt og fedme
CN111388488A (zh) * 2020-04-10 2020-07-10 中国海洋大学 半乳寡糖及其衍生物在作为防治非酒精性脂肪肝药物中的应用
US12508274B2 (en) 2020-07-17 2025-12-30 Dsm Nutritional Products, Llc Oligosaccharide compositions and methods of use
BE1028339B1 (fr) 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
WO2022155443A1 (en) * 2021-01-15 2022-07-21 Yale University Compositions and methods for treating and preventing diseases or disorders using inter-species interactions
US20240268432A1 (en) 2021-07-23 2024-08-15 Universidade Católica Portuguesa - Ucp Encapsulated bacterial, methods and uses thereof
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100172874A1 (en) * 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
CN101983237A (zh) * 2007-12-24 2011-03-02 康斯乔最高科学研究公司 改善与谷蛋白摄入相关之病症个体健康状况的微生物

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1423823A (fr) 1964-11-20 1966-01-07 Azote Office Nat Ind Procédé de reformage catalytique et sous pression élevée des hydrocarbures pétroliers par la vapeur
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5143845A (en) 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
GB9306473D0 (en) 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
CA2269806C (en) 1996-10-28 2006-01-24 Bernhard H. Van Lengerich Embedding and encapsulation of controlled release particles
AU6049599A (en) 1998-09-17 2000-04-03 Baxter Healthcare Sa Streptococcal c beta protein compositions
WO2000035465A2 (en) 1998-12-11 2000-06-22 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
ES2321797T3 (es) 1999-08-05 2009-06-12 Societe Des Produits Nestle S.A. Bifidobacterias que previenen la diarrea causada por bacterias patogenicas.
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
WO2002062360A1 (en) 2001-02-06 2002-08-15 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
JP2005526038A (ja) 2002-02-21 2005-09-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 皮膚の光防護のための経口投与可能な組成物
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1462116A1 (en) 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050100559A1 (en) 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
MXPA06015184A (es) 2004-06-23 2007-11-22 Nestec Sa Procedimiento y composiciones utiles para prevenir y/o tratar pieles sensibles y/o secas.
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20041550A1 (it) 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
FR2874825B1 (fr) 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
WO2006050166A2 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
US8728794B2 (en) 2004-12-28 2014-05-20 Meiji Seika Pharma Co., Ltd. Strain conferring anti-disease properties to host and bacterial cell composition
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
US20070042953A1 (en) 2005-08-16 2007-02-22 Bazan Nicolas G Antiepileptogenic complex of albumin with docosahexaenoate
FR2889958A1 (fr) 2005-08-25 2007-03-02 Lyoct Sa Lab Utilisation d'un symbiotique pour le traitement de la dermatite atopique
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
ITRM20060237A1 (it) 2006-05-03 2007-11-04 Anabasis S R L Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche
EP2040724B1 (en) * 2006-05-18 2011-10-05 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof
CN1850047A (zh) * 2006-06-01 2006-10-25 济南帅华医药科技有限公司 一种含β－内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US9644210B2 (en) 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
BRPI0809448A2 (pt) 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
EP2134833B1 (en) 2007-03-28 2016-03-09 Alimentary Health Limited Probiotic bifidobacterium strain
BRPI0811079A2 (pt) 2007-05-03 2014-10-21 Tobias Olofsson Bactérias isoladas de mel fresco ou do trato produtor de mel de abelhas melíferas
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
DK1992351T3 (en) 2007-05-18 2016-06-06 Nestec Sa Lactobacillus johnsonii for the prevention of post-surgical infection
US20090010891A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Sepsis Treatment Agent
US20090010892A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Hyperlipidemia Treatment Agent
EP2184997A4 (en) 2007-07-31 2010-11-03 Univ New York DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2192909A2 (en) 2007-10-01 2010-06-09 University College Cork-National University of Ireland, Cork Modulation of tissue fatty acid composition of a host by human gut bacteria
US8478544B2 (en) 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
US20090143759A1 (en) 2007-11-30 2009-06-04 Jacques Van Dam Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
DK2318513T3 (da) 2008-07-11 2012-10-22 Chr Hansen As Ny probiotisk bifidobacterium longum
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
MX356598B (es) 2008-11-11 2018-06-04 Alimentary Health Ltd Bifidobacterium longum.
EP2427499A1 (en) 2009-05-07 2012-03-14 Tate&Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
US10576110B2 (en) 2009-05-11 2020-03-03 Societe Des Produits Nestle S.A. Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders
US20150320808A1 (en) 2009-06-19 2015-11-12 Dupont Nutrition Biosciences Aps Bifidobacteria for treating cardiac conditions
CN104784220A (zh) 2009-06-19 2015-07-22 杜邦营养生物科学有限公司 治疗糖尿病及相关病症的双歧杆菌
US9848760B2 (en) 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
EP2459203B1 (en) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
CA2776420A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011060123A1 (en) 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
US20130108585A1 (en) 2009-12-16 2013-05-02 Giovanni Mogna Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
JP5578375B2 (ja) 2010-02-10 2014-08-27 日環科学株式会社 好熱性微生物を用いた混合物、溶解液、及び医薬品
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
JP5903380B2 (ja) 2010-06-28 2016-04-13 株式会社ヤクルト本社 経口用皮膚性状改善剤
WO2012000962A2 (en) 2010-06-30 2012-01-05 Nestec S.A. Use of chicoric acid and lactic bacterium in food supplement for regulating skin pigmentation
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
EP2613802A4 (en) 2010-09-10 2014-03-26 Viropharma Inc ENVIRONMENTAL CLOSTRIDAL BACTERIOTHERAPY AND ASSOCIATED FORMULATIONS AND METHODS OF MAKING AND USING SAME
EP2944690B1 (en) 2010-10-11 2017-12-20 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
CN103687604A (zh) 2011-03-01 2014-03-26 群体创新有限责任公司 用于治疗与致病生物膜相关之病症的材料和方法
US9968638B2 (en) * 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
JP5877902B2 (ja) 2011-08-17 2016-03-08 マイクロバイオーム セラピューティクス，エルエルシー バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用
WO2013024178A1 (en) 2011-08-18 2013-02-21 Chr. Hansen A/S Method for purifying bacterial cells
KR101982491B1 (ko) 2011-08-30 2019-05-27 아카데미쉬 메디쉬 센트륨 인슐린 저항 예방 및/또는 치료 방법
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
US9649346B2 (en) 2011-11-02 2017-05-16 Bios Llc Probiotic stick formulation for skin maintenance and methods of use
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
KR20150000867A (ko) 2011-12-07 2015-01-05 칼피스가부시키가이샤 유산균 또는 그 처리물을 포함한 지질대사 및/또는 당대사 개선제
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
US20130344042A1 (en) 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
WO2014011233A1 (en) 2012-07-09 2014-01-16 Trachtman Ira Milton Compositions and method for treatment and prophylaxis of inflammatory bowel disease
DK2885395T3 (da) 2012-08-20 2020-11-30 Chr Hansen As Fremgangsmåde til frysetørring af et bakterieholdigt koncentrat
CA2885537C (en) 2012-09-20 2021-11-23 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
BR112015009975A2 (pt) 2012-11-01 2017-07-11 Academisch Ziekenhuis Groningen métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinal
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP4509181A3 (en) 2012-11-19 2025-05-21 Université Catholique de Louvain Utilisation d'akkermansia pour le traitement de troubles métaboliques
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
EP2971148A4 (en) 2013-03-14 2016-08-17 Seres Therapeutics Inc METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN105106245A (zh) 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100172874A1 (en) * 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
CN101983237A (zh) * 2007-12-24 2011-03-02 康斯乔最高科学研究公司 改善与谷蛋白摄入相关之病症个体健康状况的微生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUSEN ZHANG等: "Human gut microbiota in obesity and after gastric bypass", 《PNAS》 *

Also Published As

Publication number Publication date
US20200246395A1 (en) 2020-08-06
US11590176B2 (en) 2023-02-28
CN110201003A (zh) 2019-09-06
US10149870B2 (en) 2018-12-11
WO2013130773A8 (en) 2014-10-16
US10729732B2 (en) 2020-08-04
BR112014021388A2 (pt) 2017-07-18
IN2014DN07752A (https=) 2015-05-15
US10149867B2 (en) 2018-12-11
WO2013130773A2 (en) 2013-09-06
US20200121734A1 (en) 2020-04-23
US20170368108A1 (en) 2017-12-28
US20130224155A1 (en) 2013-08-29
US9173910B2 (en) 2015-11-03
US20200121733A1 (en) 2020-04-23
US20190046590A1 (en) 2019-02-14
CN104780932A (zh) 2015-07-15
WO2013130773A3 (en) 2014-12-18
EP2836224A2 (en) 2015-02-18
US20160113971A1 (en) 2016-04-28
US20200121732A1 (en) 2020-04-23
EP2836224A4 (en) 2015-12-16
US20200121735A1 (en) 2020-04-23
US20200237835A1 (en) 2020-07-30
US12048721B2 (en) 2024-07-30
US20200121736A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
US12048721B2 (en) Compositions of microbiota and methods related thereto
Wang et al. Gut microbiota mediates the anti-obesity effect of calorie restriction in mice
Villanueva-Millán et al. Gut microbiota: a key player in health and disease. A review focused on obesity
Spanogiannopoulos et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Ojeda et al. Nutritional modulation of gut microbiota—The impact on metabolic disease pathophysiology
Furet et al. Differential adaptation of human gut microbiota to bariatric surgery–induced weight loss: links with metabolic and low-grade inflammation markers
Su et al. Lotus seed oligosaccharides at various dosages with prebiotic activity regulate gut microbiota and relieve constipation in mice
US20180028576A1 (en) Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
US20170151290A1 (en) Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
JP2018532779A (ja) 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル
Chiou et al. Gut microbiota-directed intervention with high-amylose maize ameliorates metabolic dysfunction in diet-induced obese mice
Li et al. The synergism of Lactobacillaceae, inulin, polyglucose, and aerobic exercise ameliorates hyperglycemia by modulating the gut microbiota community and the metabolic profiles in db/db mice
JP6475162B2 (ja) プレバイオティックチラコイド組成物
Jia et al. The potential auxiliary effects of Sargassum fusiform polysaccharides on sitagliptin in the treatment of diabetes mellitus
US20220325323A1 (en) Skin microbiome monitoring for improving systemic health
Wu et al. GOS‐Modulated Gut Microbiota in Mice Ameliorates Obesity in High‐Fat Diet‐Fed Mice Through the Gut‐Liver Axis and Bile Acid Pathway
Jordan Nelson Influence of Gut Microbiota–Derived Short-Chain Fatty Acids on Insulin Sensitivity in Type 2 Diabetes Mellitus
Poeker Towards understanding the modulation potential of dietary fibers on intestinal microbiota using human and a novel murine intestinal fermentation model
Fåk The gut microbiota: a predisposing factor in obesity, diabetes and atherosclerosis
Basso et al. Microbiota Organ and Bariatric Surgery
Wang et al. 922 Angiotensin Converting Enzyme Modulates Epithelial Cell Apoptosis in a Massive Intestinal Resection Rat Model: Role of At1r Receptor
Barnes et al. 923 The Addition of Synbiotics to Partial Enteral Nutrition Enhances Intestinal Adaptation in a Piglet Model of Intestinal Failure
Ramadass et al. 924 Glutamine Attenuates the Toxic Effects of Legumes via Stimulation of HSP Production
Rodier by Hugo Rodier, MD
Henrick et al. Nutritional Microbiology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230406

Address after: new jersey

Applicant after: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc.

Applicant after: THE GENERAL Hospital Corp.

Applicant after: PRESIDENT AND FELLOWS OF HARVARD College

Address before: Ohio State

Applicant before: ETHICON ENDO-SURGERY, Inc.

Applicant before: THE GENERAL Hospital Corp.

Applicant before: PRESIDENT AND FELLOWS OF HARVARD College